文献速递头颈与中枢神经肿瘤

中国南方鼻咽癌筛查集群随机试验中期分析:EBV抗体筛查的发病与死亡

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.
PubMed 文献 · Ann Oncol · 2019-01-01

PRO-NPC-001试验在中国南方开展集群随机对照筛查,采用两种抗EBV抗体检测。中期分析显示筛查参与者鼻咽癌早期诊断率显著提高,筛查组与对照组鼻咽癌特异死亡率无显著差异,但参与筛查者死亡率显著降低。

要点

  • EBV抗体筛查可识别高危人群并有效筛查早期无症状鼻咽癌。
  • 筛查参与者鼻咽癌早期诊断率79.0%,显著高于对照组的20.6%。
  • 参与筛查者鼻咽癌特异死亡率显著低于对照组(RR=0.22)。

核心结论

  • EBV IgA抗体可识别高危人群并有效筛查早期无症状鼻咽癌。
  • 主要终点筛查组与对照组鼻咽癌特异死亡率无显著差异,但筛查参与者死亡率降低有鼓励性证据。

研究设计与样本

  • 前瞻性集群随机对照试验(PRO-NPC-001),2008年起在中国南方中山市3个镇和四会市13个镇开展。
  • 筛查组检测两种抗EBV抗体,中风险者每年复检持续3年,高风险者转诊耳鼻喉科诊断检查。

主要发现

  • 筛查参与者鼻咽癌早期诊断率79.0%(P<0.0001),筛查组45.9%(P<0.0001),对照组20.6%。
  • 筛查组与对照组鼻咽癌特异死亡率无差异(RR=0.82,95%CI 0.37-1.79)。
  • 筛查参与者较对照组鼻咽癌特异死亡率降低(RR=0.22,95%CI 0.09-0.49)。

临床怎么用

  • 在鼻咽癌高发区可采用EBV抗体筛查识别高危人群并促进早期诊断。
  • 筛查参与者死亡率降低的鼓励性证据支持进一步评估筛查对死亡率的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous mass screening studies have shown that IgA antibodies against Epstein-Barr Virus (EBV) can facilitate early detection of nasopharyngeal carcinoma (NPC), but the impact of EBV-antibody screening for NPC-specific mortality remains unknown. PATIENTS AND METHODS: A prospective, cluster randomized, controlled trial for NPC screening (PRO-NPC-001) was conducted in 3 selected towns of Zhongshan City and 13 selected towns of Sihui City in southern China beginning in 2008. Serum samples of the screening group were tested for two previously selected anti-EBV antibodies. Subjects with serological medium risk were subsequently retested annually for 3 years, and those with serological high risk were referred to otorhinolaryngologists for diagnostic check-up. An interim analysis was carried out to evaluate the primary end points of the NPC-specific mortality and the early diagnostic rate, and the secondary end point of the NPC incidence, through linkage with the database of Zhongshan City. RESULTS: Among 70 296 total subjects, 29 413 screened participants (41.8% of the total subjects) in the screening group and 50 636 in the control group, 153 (43.3 per 100 000 person-year), 62 (55.3 per 100 000 person-year) and 99 (33.1 per 100 000 person-year) NPC cases were identified. The early diagnostic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%). Although no differences were found between NPC-specific mortality of the screening group and the control group [relative risk (RR)= 0.82, 95% confidence interval (CI) 0.37-1.79], lower NPC-specific mortality was noticed among participants from the screening group versus the control group (RR = 0.22, 95% CI 0.09-0.49). CONCLUSION: IgA antibodies against EBV can identify high-risk population and was effective in screening for early asymptomatic NPC. Although the mortality reduction was not significant in the primary end point, we noted encouraging evidence of a mortality reduction in screening participants in this interim analysis. CLINICAL TRIAL NUMBER: NCT00941538.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ji MF, Sheng W, Cheng WM, et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019. PMID: 31373615. doi:10.1093/annonc/mdz231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。